Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age

PHASE3CompletedINTERVENTIONAL
Enrollment

1,134

Participants

Timeline

Start Date

April 20, 2022

Primary Completion Date

October 5, 2022

Study Completion Date

October 5, 2022

Conditions
SARS-CoV-2 InfectionCOVID-19
Interventions
BIOLOGICAL

BNT162b2

Intramuscular injection

OTHER

Placebo

Saline intramuscular injection

BIOLOGICAL

Seasonal Inactivated Influenza Vaccine

SIIV intramuscular injection

Trial Locations (26)

1010

New Zealand Clinical Research (Auckland), Grafton

Optimal Clinical Trials, Grafton

2025

Aotearoa Clinical Trials, Auckland

Middlemore Clinical Trials, Auckland

2100

Northern Beaches Clinical Research, Brookvale

2145

Westmead Hospital, Westmead

3010

Pacific Clinical Research Network - Rotorua, Rotorua

3110

P3 Research - Tauranga, Tauranga

3118

Lakeland Clinical Trials Culloden, Papamoa Beach

3124

Emeritus Research, Camberwell

3200

Lakeland Clinical Trials Waikato, Hamilton

3220

Barwon Health, Geelong

4010

Paratus Clinical Research Brisbane, Albion

4121

AusTrials - Wellers Hill, Wellers Hill

4130

P3 Research - Hawke's Bay, Havelock North

4414

P3 Research - Palmerston North, Palmerston North

5018

Lakeland Clinical Trials Wellington, Ebdentown. Upper Hutt

5032

P3 Research - Kapiti, Paraparaumu

6021

Capital, Coast and Hutt Valley District - Wellington Regional Hospital, Wellington

P3 Research - Wellington, Wellington

7011

Southern Clinical Trials Tasman, Nelson

8011

New Zealand Clinical Research (Christchurch), Christchurch

8013

Pacific Clinical Research Network - Forte, Christchurch

NSW 2035

Australian Clinical Research Network, Sydney

0600

Southern Clinical Trials Totara, New Lynn

0626

Southern Clinical Trials Waitemata Ltd, Auckland

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

BioNTech SE

INDUSTRY